November 4, 2025 – Qingdao Baheal Medical INC. (Stock Code: 301015.SZ) today announced it has entered into an expanded collaboration with global biotechnology leader CSL to strengthen their presence in China’s plasma-derived therapies sector. Under the agreement, Baheal Medical will hold exclusive promotion, marketing, and distribution rights for CSL’s albumin product Alburex® in specified markets within mainland China. This partnership builds upon the companies’ initial retail market cooperation established in 2018 and aims to fully integrate CSL’s globally leading plasma-derived therapies with Baheal’s professional commercialization platform. The move is designed to better serve the growing demand for high-quality plasma-derived products in China and expand patient access.

On October 23, 2025, Qingdao Baheal Medical INC. (Stock Code: 301015.SZ)) signed a strategic cooperation agreement with Peking University International Hospital to jointly establish a Precise Radiotherapy Center. This center is set to be established at Peking University International Hospital, and will be equipped with ZAP-X® Gyroscopic Radiosurgery™ Platform, the core product of ZAP Surgical, which is the portfolio company of Baheal Medical. This cooperation will focus on disease-specific treatment for brain tumors, offering millions of patients innovative precision radiotherapy solutions.

Recently, the 67th Annual Meeting of ASTRO (the American Society for Radiation Oncology), the world’s largest and most influential academic gathering in radiation oncology, was held in San Francisco, drawing over 10,000 top radiotherapy experts and scholars globally. At the meeting, Baheal Pharma’s (stock code: 301015.SZ) portfolio company — pioneering radiosurgery company ZAP Surgical — debuted its leading brain tumor stereotactic radiotherapy robot, the ZAP-X® Gyroscopic Radiosurgery™ Platform. The company showcased the platform’s latest clinical breakthroughs and clinical data.

On September 12, 2025, Qingdao Baheal Medical INC. (Stock Code: 301015.SZ) entered into a strategic collaboration with Tianjin JiKun Medicine Technology Co., Ltd. As part of this agreement, Baheal will acquire a 24% stake in JiKun Medicine, securing full rights to its Class I innovative drug for pulmonary fibrosis. In addition, Baheal gains the right of first refusal—under equivalent terms—on the global compound rights of all JiKun pipeline assets.

Recently, BrioHealth Solutions, Inc., a wholly-owned subsidiary of BrioHealth in the United States, announced that its independently developed fully magnetic levitation left ventricular assist device, BrioVAD, has formally received approval from FDA to advance to the Pivotal Phase of its clinical trial following the successful completion of the Safety Phase of the INNOVATE clinical trial in the United States. The FDA has approved expanding the clinical research centers to 60 sites, with a cumulative enrollment of up to 780 subjects (including those enrolled during the Safety Phase).